Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
1 Feb 24
8-K
Termination of a Material Definitive Agreement
5 Dec 23
10-Q
2024 Q1
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
8-K
Changes in Registrant's Certifying Accountant
30 Oct 23
10-K
2023 FY
Annual report
28 Sep 23
10-Q
2023 Q3
Quarterly report
15 May 23
10-Q
2023 Q2
Quarterly report
15 Feb 23
NT 10-Q
Notice of late quarterly filing
15 Feb 23
8-K
Other Events
4 Jan 23
10-Q
2023 Q1
Quarterly report
10 Nov 22
10-K
2022 FY
Annual report
28 Sep 22
8-K
Entry into a Material Definitive Agreement
15 Jun 22
10-Q
2022 Q3
Quarterly report
13 May 22
10-Q
2022 Q2
Quarterly report
14 Feb 22
10-Q
2022 Q1
Quarterly report
9 Nov 21
8-K
Departure of Directors or Certain Officers
14 Oct 21
10-K
2021 FY
Annual report
27 Sep 21
10-Q
2021 Q3
Quarterly report
13 May 21
10-Q
2021 Q2
Quarterly report
22 Feb 21
NT 10-Q
Notice of late quarterly filing
17 Feb 21
8-K
Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives
15 Jan 21
8-K
FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals’ Brilacidin for Treating COVID-19
22 Dec 20
424B5
Prospectus supplement for primary offering
10 Dec 20
8-K
Entry into a Material Definitive Agreement
10 Dec 20
8-K
Innovation Pharmaceuticals Announces Overseas Regulatory Filing Submitted For COVID-19 Clinical Study
16 Nov 20
10-Q
2021 Q1
Quarterly report
16 Nov 20
8-K
Regulation FD Disclosure
2 Nov 20
8-K
Innovation Pharmaceuticals Announces Pre-IND Meeting Request Granted by FDA for the Study of Brilacidin for the Treatment of COVID-19
2 Oct 20
8-K
Laboratory Testing of Brilacidin for COVID-19 in Combination with Remdesivir Reduces Viral Load by Nearly 100 Percent
15 Sep 20
10-K
2020 FY
Annual report
14 Sep 20
424B5
Prospectus supplement for primary offering
4 Aug 20
8-K
Innovation Pharmaceuticals and U.S. Regional Biocontainment Laboratory Nearing Completion of Brilacidin Anti-SARS-CoV-2 (COVID-19) In Vitro Testing
4 Aug 20
8-K
Regulation FD Disclosure
22 Jul 20
8-K
Regulation FD Disclosure
20 Jul 20
EFFECT
Notice of effectiveness
20 Jul 20
CORRESP
Correspondence with SEC
15 Jul 20
UPLOAD
Letter from SEC
15 Jul 20
S-3
Shelf registration
10 Jul 20
8-K
Regulation FD Disclosure
19 Jun 20
Latest ownership filings
4
LEO EHRLICH
4 Jan 23
4
Jane A. Harness
28 Sep 22
4
LEO EHRLICH
28 Sep 22
4
Zorik Spektor
28 Sep 22
4
Barry A Schechter
28 Sep 22
SC 13G/A
Kips Bay Select LP
5 Jul 22
SC 13G/A
Kips Bay Select LP
3 May 21
SC 13G
Kips Bay Select LP
11 Feb 21
SC 13G/A
Leviston Resources LLC
15 Jul 20
SC 13G
Leviston Resources LLC
10 Jul 20
4
LEO EHRLICH
1 Apr 20
4
Jane A. Harness
6 Sep 19
4
Arthur Peter Bertolino
6 Sep 19
4
LEO EHRLICH
31 Jan 19
SC 13G/A
Innovation Pharmaceuticals Inc.
22 Jan 19
4
Jane A. Harness
16 Oct 18
4
Arthur Peter Bertolino
15 Oct 18
4
Arthur Peter Bertolino
24 Sep 18
4
Jane A. Harness
24 Sep 18
SC 13G/A
Innovation Pharmaceuticals Inc.
11 Jan 18
4
Arthur Peter Bertolino
27 Dec 17
4
Arthur Peter Bertolino
6 Sep 17
4
Jane A. Harness
6 Sep 17
3
Jane A. Harness
8 Aug 17
5
Arthur Peter Bertolino
8 Aug 17
5
Jane A. Harness
8 Aug 17
5
LEO EHRLICH
8 Aug 17
SC 13G/A
Cellceutix CORP
28 Apr 17
SC 13G/A
Cellceutix CORP
4 Jan 17
3
Zorik Spektor
11 Jul 16
4
Zorik Spektor
11 Jul 16
3
Arthur Peter Bertolino
7 Jul 16
3
Mark Robert Tobin
7 Jul 16
3
Barry A Schechter
7 Jul 16
4
Arthur Peter Bertolino
7 Jul 16
4
Mark Robert Tobin
7 Jul 16
4
Barry A Schechter
7 Jul 16
SC 13G/A
Cellceutix CORP
27 Jan 16
4
Krishna Menon
18 Dec 15
SC 13G/A
Cellceutix CORP
5 Feb 15